00:00
The NHS is 75 years old and is unwell. Patients with a suspected heart attack are waiting five times longer for an ambulance than the 18-min target. In 2022, 347 707 patients spent more than 12 h in Accident and Emergency departments waiting for a bed, four times as many as in the previous 10 (...) (The Lancet 401, 10373 (2023))
00:00
Myelofibrosis is a progressive chronic myeloproliferative neoplasm driven by Janus kinase and signal transducer and activator of transcription (JAK–STAT) pathway activation, mostly due to mutations in JAK2, MPL, and CALR.1 Myelofibrosis arises de novo (primary myelofibrosis) or secondarily from (...) (The Lancet 401, 10373 (2023))
00:00
Marburg virus disease is a severe infection in people and non-human primates (NHPs), with a case-fatality rate of 23–90%.1 The disease is caused by the Marburg virus, a member of the Filoviridae family, which includes the viruses responsible for Ebola virus disease.1 Marburg virus disease is (...) (The Lancet 401, 10373 (2023))
00:00
Yes, the US will remain a dominant force in global health for the foreseeable future. But Shannon K O’Neil, in her provocative book The Globalization Myth, casts doubt on the sustainability of America's influence. First, the positive. The US is wealthy and has vastly skilled human resources to (...) (The Lancet 401, 10373 (2023))
00:00
A new mental health law is hoped to transform care for patients in Nigeria. Paul Adepoju reports from Ibadan, Nigeria. (The Lancet 401, 10373 (2023))
00:00
New legislation to curb the harms of tobacco is among the strongest in the world. Sharmila Devi reports. (The Lancet 401, 10373 (2023))
00:00
For almost 30 years, contributors to ProMED-mail have flagged new and emerging infectious threats to health. Talha Burki reports. (The Lancet 401, 10373 (2023))
00:00
As a young child in apartheid era South Africa, Lynette Denny saw police regularly raid the quarters of her family's domestic staff to find Black people who did not have the documents they were legally required to carry to prove their identity and employment. It left Denny with “a permanent (...) (The Lancet 401, 10373 (2023))
00:00
Bearing the weight of a traumatic history, medical research is often seen as invasive and harmful by subaltern communities. The term subaltern, originating from postcolonial theory, refers to socio-politically silenced groups that are excluded from inner circles of colonial power. Western (...) (The Lancet 401, 10373 (2023))
00:00
Epidemiologist and authority on thrombogenesis and heart disease. He was born in Oxford, UK, on Jan 21, 1936 and died of a lower respiratory tract infection in London, UK, on Oct 24, 2022 aged 86 years. (The Lancet 401, 10373 (2023))
00:00
We read with interest Xin Ni and colleagues'1 study on cancer incidence, and the association between incidence and inaccessibility of health services among children and adolescents in China. The authors found that an estimated 121 145 cancer cases were diagnosed among children and adolescents (...) (The Lancet 401, 10373 (2023))
00:00
We thank Yaping Wang and Jue Liu for their Correspondence in response to our Article1 about socioeconomic inequalities in cancer incidence and access to health services faced by Chinese children and adolescents. (The Lancet 401, 10373 (2023))
00:00
Richard Horton argues that an academic health science system must possess societal goals and promote social cohesion and public trust.1 Indeed, medical education should help to promote better health outcomes for vulnerable populations and disadvantaged communities. However, to this end, it is (...) (The Lancet 401, 10373 (2023))
00:00
The pre-eminence of research over teaching in academic activity might be considered as an inheritance from the Enlightenment and, in the past few decades, from evidence-based medicine. Within this framework, teaching is secondary to research because the former is built, at least in part, on the (...) (The Lancet 401, 10373 (2023))
00:00
Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400: 1927–37—For this Article, the PRECISION investigators list has been updated. This correction (...) (The Lancet 401, 10373 (2023))
00:00[Articles] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study -
Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N Harrison, Barbara J Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa, on behalf of MOMENTUM Study (...)
Lancet
Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in myelofibrosis-associated symptoms, anaemia measures, and spleen response, with favourable safety. These findings support the future use of momelotinib as an effective treatment in patients with (...) (The Lancet 401, 10373 (2023))
00:00[Articles] Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial -
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Christine Lee, Anne Preston, Brooke Augustine, Charla Andrews, Galina V Yamshchikov, Somia Hickman, Steven Schech, Jack N Hutter, Paul T Scott, Paige E Waterman, Mihret F Amare, Victoria Kioko, Casey Storme, Kayvon Modjarrad, Melanie D McCauley, Merlin L Robb, Martin R Gaudinski, Ingelise J Gordon, LaSonji A Holman, Alicia T Widge, Larisa Strom, Myra Happe, Josephine H Cox, Sandra Vazquez, Daphne A Stanley, Tamar Murray, Caitlyn N M Dulan, Ruth Hunegnaw, Sandeep R Narpala, Phillip A Swanson, Manjula Basappa, (...)
Lancet
This first-in-human trial of this cAd3-Marburg vaccine showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. 95% of participants produced a glycoprotein-specific antibody response at 4 weeks after a single vaccination, (...) (The Lancet 401, 10373 (2023))
00:00
A 37-year-old woman presented to our emergency room reporting chest pain and palpitations which had woken her up in the early hours of the morning. She was known to be homozygous for a rare and severe form of cystic fibrosis with a mutation, described among Jewish people of Georgian descent, in (...) (The Lancet 401, 10373 (2023))